XML 50 R17.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Capitalized Fees Paid | 12 Months Ended
--- | ---
Dec. 31, 2024
Capitalized Contract Cost [Abstract] |
CAPITALIZED FEES PAID | 7. CAPITALIZED FEES PAID Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:
|  |  |  | December 31, |
(In thousands) |  | Amortization period |  | 2024 |  |  | 2023 |
United States |  | 2013-2030 |  | $ | 120,000 |  |  | $ | 120,000 |
Europe |  | 2013-2029 |  |  | 60,000 |  |  |  | 60,000 |
Japan |  | 2013-2029 |  |  | 40,000 |  |  |  | 40,000 |
Gross carrying value |  |  |  |  | 220,000 |  |  |  | 220,000 |
Accumulated amortization |  |  |  |  | (150,039 | ) |  |  | (136,216 | )
Net carrying value |  |  |  | $ | 69,961 |  |  | $ | 83,784 |
These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2024, the weighted average remaining amortization period wa s 5.2 years. Additional information regarding these milestone fees is included in Note 3, “Revenue Recognition”. Amortization for each of the years ended December 31, 2024, 2023 and 2022 was $13.8 million. The remaining estimated amortization is $13.8 million for each of the years from 2025 to 2027, $13.7 million for the year 2028, $9.4 million for the year 2029 and $5.4 million thereafter.

X
- Definition The entire disclosure for information about capitalized fees paid. + References No definition available. + Details
Name: | inva_CapitalizedFeesPaidDisclosureTextBlock
Namespace Prefix: | inva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CapitalizedContractCostAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration